OSLO, Norway--(BUSINESS WIRE)--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback